Skip to content

Homoeopathic treatment of Migraine

Efficacy of Individualized Homoeopathic Medicines for Migraine among adults; Double blind, Randomized, Placebo controlled Clinical Trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044049
Enrollment
86
Registered
2022-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: Individualized Homoeopathic Medicines: Administration of indicated homoeopathic medicines in centesimal potencies as per the need of the patient and as decided appropriate by the invest

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects who has diagnosed as per the International classification of Headache disorders diagnostic criteria - 3 for Migraine. 2. Subjects will be selected irrespective of their sex, socio-economic status and occupation. 3. Age between 18 to 50 years. 4. If the subject is illiterate then the relatives or family members will be assessed to fill the headache diary. 5. Subjects who are willing to participate and sign the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Subjects suffering from the complications of migraine. 2. Suspected secondary headache (trauma, headache attributed to vascular or non vascular intracranial disorders, medication overuse headache, hypertension). 3. Subjects are undergoing treatment with non-steroidal anti inflammatory drugs (NSAIDS), antiemetic, triptans, ergot alkaloids and oestrogen during 2 weeks prior to enrollment in the study. 4. Subjects suffering from uncontrolled systemic illness or psychiatric diseases and/or life-threatening infections. 5. Substance abuse and/or dependence. 6. Pregnant or lactating women. 7. Subjects already undergoing homoeopathic treatment elsewhere for any chronic disease within last 02 months. 8. Non-compliance to the study treatment/ protocol.

Design outcomes

Primary

MeasureTime frame
Diagnostic Headache Diary (DHD)Timepoint: Baseline, every month, up to 6 months

Secondary

MeasureTime frame
EQ-5D-5L and EQ-VAS QuestionnaireTimepoint: Baseline, 3 month, 6 months;Migraine Disability Assessment Questionnaire (MIDAS)Timepoint: Baseline, 3 months, 6 months

Countries

India

Contacts

Public ContactDr Hanuman Ram

Homoeopathy University, Jaipur, Rajasthan

drsoniatuteja@yahoo.in9530454132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026